OR WAIT 15 SECS
Catalent has acquired Micron Technologies, a provider of particle size engineering technologies.
Catalent announced on Nov. 13, 2014 that it has acquired Micron Technologies, a provider of particle size engineering technologies. The addition of Micron Technologies’ particle engineering capabilities is part of Catalent’s strategy to expand its portfolio of drug delivery technologies and drug development offerings to address bioavailability, stability, and manufacturability challenges.
Catalent’s services range from OptiForm API optimization and Micron Technologies particle size optimization, formulation development and final dose form design, to bioavailability solutions, such as RP Scherer Softgel lipid systems and OptiMelt hot melt extrusion technologies.
Catalent will be able to partner with more pharmaceutical innovators and support their drug development activities from early stage through to scale-up, clinical and commercial manufacturing of finished oral and inhaled dosage forms, including highly potent compounds.
This is Catalent’s second acquisition since its IPO in July. In October 2014, Catalent acquired Redwood Bioscience, with its SMARTag Antibody-Drug Conjugate (ADC) technology platform, in October 2014.
Micron Technologies currently operates two state-of-the-art facilities, with excellent quality and regulatory compliance records, in Malvern, PA, and in Dartford, U.K., and employs approximately 100 people across both sites. Micron Technologies has over 25 years of experience in air jet milling micronization and is capable of processing R&D and commercial volumes at both of its sites. Micron Technologies currently supports active programs involving over 300 customers from around the world. Both facilities are equipped with advanced systems to ensure the quality, safety and total containment of highly potent and cytotoxic compounds, and provide integrated analytical services capabilities from early stage development to commercialization.